Reuters
The results suggest that Zipbound may be a superior treatment for weight loss, helping obese or overweight patients lose an average of 20.2 percent of their body weight, or about 50 pounds, after 72 weeks in a phase three trial. It helps to do. Meanwhile, Vigovi helped people lose an average of 13.7% of their weight, or about 33 pounds, after the same period.
Eli Lilly said Zipbound provided a 47 percent greater relative weight loss than Vigovi in the trial. The company added that more than 31% of people taking ZipBound lost at least a quarter of their body weight, compared to only 16% of people on Vegovi who lost that much weight.
Along with separate studies on drugs a Recent head-to-head analysis Health Records, likewise indicated that Zepbound outperforms Wegovy in terms of weight loss. A late study on ZipBound showed that it helped patients lose weight. More than 22 percent of their weight over 72 weeks on average, while a separate study on Vigovi showed that because 15% weight loss More than 68 weeks on average.
But Wednesday’s data appears to be the most concrete evidence of Zipbound’s edge, as the trial randomly assigned 751 patients to receive the maximum dose of either drug. The study specifically followed patients who were obese or overweight with at least one weight-related medical condition, including diabetes.
Dr. Leonard Glass, senior vice president of global clinical affairs for Eli Lilly Cardiometabolic Health, said in a release, “Given the growing interest in obesity medicine, we conducted this study to inform healthcare providers and patients about the treatment. to help make informed decisions about the choice of .
Eli Lilly is still reviewing the findings, which it plans to publish in a peer-reviewed journal and present at a medical meeting next year.
The most common side effects of both drugs were gastrointestinal and generally mild to moderate.
Zipbound’s high weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a large share of the growing weight loss drug market. Some analysts expect the space to be worth $150 billion a year by the early 2030s.
Vigovi entered the market nearly two years before ZipBound, which won approval in the U.S. in late 2023. Still, some analysts believe Zipbound has a great shot at becoming the best-selling drug of all time after more years on the market.
Data analytics firm GlobalData Prophecy According to data from November, Zepbound will generate $27.2 billion in annual sales by 2030 and Wegovi will book $18.7 billion in annual revenue by the same year.
Over the past year, demand for Zipbound, Vigovi and their diabetes counterparts has outstripped supply, forcing Eli Lilly and Novo Nordisk to spend billions to ramp up their production capacity for the injection. has been done These efforts appear to be paying off, as the Food and Drug Administration now lists all doses of these treatments. “Available” on its drug shortage database.
Still, some patients struggle to access the drugs without insurance or other savings on weight loss treatments in the U.S. Both Zepbound and Wegovy cost about $1,000.
Treatments work differently.
Zipbound suppresses appetite and regulates blood sugar by activating two gut hormones, called GIP and GLP-1. Vigovi activates GLP-1 but does not target GIP, which some researchers say may also affect how the body breaks down sugar and fat.